Table 1

Patient characteristics

PatientAge (yr)GenderDiagnosisMetastatic (site)Prior chemotherapy
164FaMFHY (lungs)A+ I
241MLiposarcomaNNone
320MEwing’s sarcomaY (lungs+ ST+ B)A+ I+ DTIC+ VP16+ CP+ CX+ V
461MAngiosarcomaNNone
558FMFHY (lungs)A+ I+ DTIC
619FEwing’s sarcomaY (ST+ B)A+ I+ DTIC+ VP16+ CP+ CX
734FSynovial sarcomaY (lungs)A+ I, I, A+ CX
845MLeiomyosarcomaY (lungs)A+ I
936FCardiac sarcomaY (lungs+ ST+ P)A+ I
1048MSynovial sarcomaY (lungs)A+ I+ DTIC
1130FASPSY (lungs)A+ I, V+ I+ CP
1252FRP sarcoma, NOSY (liver)None
1353FSynovial sarcomaY (lungs)A+ I
1440FGI stromal tumorY (liver)Temodar, A+ I
1573MLiposarcomaY (lungs+ ST)None
1625FSynovial sarcomaY (lungs)None
  • a F, female; M, male; MFH, malignant fibrous histiocytoma; NOS, not otherwise subclassafiable; ST, soft tissue; P, pancreas; A, doxorubicin; I, ifosfamide; DTIC, dacarbazine; CP, cisplatin; CX, cytoxan; V, vincristine; Y, yes; ASPS, alveolar soft part sarcoma.